JP2015519313A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015519313A5 JP2015519313A5 JP2015507425A JP2015507425A JP2015519313A5 JP 2015519313 A5 JP2015519313 A5 JP 2015519313A5 JP 2015507425 A JP2015507425 A JP 2015507425A JP 2015507425 A JP2015507425 A JP 2015507425A JP 2015519313 A5 JP2015519313 A5 JP 2015519313A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- composition according
- amino acid
- fviii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12165296.0 | 2012-04-24 | ||
| EP12165296 | 2012-04-24 | ||
| US201261641439P | 2012-05-02 | 2012-05-02 | |
| US61/641,439 | 2012-05-02 | ||
| EP13150575 | 2013-01-09 | ||
| EP13150575.2 | 2013-01-09 | ||
| US201361752614P | 2013-01-15 | 2013-01-15 | |
| US61/752,614 | 2013-01-15 | ||
| PCT/EP2013/055107 WO2013160005A1 (en) | 2012-04-24 | 2013-03-13 | Pharmaceutical composition suitable for treatment of haemophilia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015519313A JP2015519313A (ja) | 2015-07-09 |
| JP2015519313A5 true JP2015519313A5 (https=) | 2016-04-14 |
Family
ID=49482214
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015507425A Withdrawn JP2015519313A (ja) | 2012-04-24 | 2013-03-13 | 血友病の治療に適する医薬組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20150045303A1 (https=) |
| EP (1) | EP2841091A1 (https=) |
| JP (1) | JP2015519313A (https=) |
| CN (1) | CN104411323A (https=) |
| WO (1) | WO2013160005A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2771999A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| EP2822577B1 (en) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| JP6256882B2 (ja) | 2012-02-15 | 2018-01-10 | アムニクス オペレーティング インコーポレイテッド | 第ｖｉｉｉ因子組成物、ならびに組成物の作製方法および用途 |
| TW202003554A (zh) | 2013-08-14 | 2020-01-16 | 美商百歐維拉提夫治療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| AR101060A1 (es) * | 2014-02-12 | 2016-11-23 | Novo Nordisk As | Conjugados de fviii |
| AU2015270394B2 (en) | 2014-06-06 | 2017-12-21 | Octapharma Ag | Preparation comprising Factor VIII and Von Willebrand factor peptides |
| WO2016198521A1 (en) | 2015-06-10 | 2016-12-15 | Novo Nordisk A/S | Fviii fusion proteins |
| EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
| EP3205665A1 (en) * | 2016-02-11 | 2017-08-16 | Octapharma AG | Method of separating factor viii from blood products |
| SG11201903954WA (en) | 2016-11-11 | 2019-05-30 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| ES2966835T3 (es) * | 2017-06-22 | 2024-04-24 | CSL Behring Lengnau AG | Modulación de la inmunogenicidad del FVIII por VWF truncado |
| CN108753910A (zh) * | 2018-05-16 | 2018-11-06 | 浙江思格医疗科技有限公司 | 一种消化液 |
| CN108918235A (zh) * | 2018-05-16 | 2018-11-30 | 绍兴文理学院 | 一种肿瘤淋巴结离体标本的固定处理方法 |
| PL3793588T3 (pl) | 2018-05-18 | 2025-09-01 | Bioverativ Therapeutics Inc. | Sposoby leczenia hemofilii a |
| JP7672334B2 (ja) * | 2018-10-23 | 2025-05-07 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | 第ｖｉｉｉ因子機能を調節するための組成物および方法 |
| WO2021001522A1 (en) * | 2019-07-04 | 2021-01-07 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
| US20220305089A1 (en) | 2019-08-16 | 2022-09-29 | Octapharma Ag | Stabilizing buffer for factor viii and vwf |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5952198A (en) * | 1995-05-04 | 1999-09-14 | Bayer Corporation | Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition |
| ES2411007T3 (es) | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
| CA2656558A1 (en) * | 2006-06-30 | 2008-01-10 | The Regents Of The University Of Michigan | Method of producing factor viii proteins by recombinant methods |
| JP2010529155A (ja) * | 2007-06-13 | 2010-08-26 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用 |
| PL2257311T3 (pl) * | 2008-02-27 | 2014-09-30 | Novo Nordisk As | Koniugaty cząsteczek czynnika VIII |
| KR20110093775A (ko) | 2008-11-03 | 2011-08-18 | 바이엘 헬스케어 엘엘씨 | 혈우병 치료 방법 |
| GB0911870D0 (en) * | 2009-07-08 | 2009-08-19 | Ucl Business Plc | Optimised coding sequence and promoter |
| JP2013519699A (ja) | 2010-02-16 | 2013-05-30 | ノヴォ ノルディスク アー／エス | 因子ｖｉｉｉ融合タンパク質 |
| JP2013532176A (ja) * | 2010-07-15 | 2013-08-15 | ノヴォ ノルディスク アー／エス | 安定化させた第ｖｉｉｉ因子バリアント |
| JP6042335B2 (ja) | 2010-09-15 | 2016-12-14 | ノヴォ ノルディスク アー／エス | 細胞取込みが低下した第ｖｉｉｉ因子変異体 |
-
2013
- 2013-03-13 WO PCT/EP2013/055107 patent/WO2013160005A1/en not_active Ceased
- 2013-03-13 US US14/396,833 patent/US20150045303A1/en not_active Abandoned
- 2013-03-13 JP JP2015507425A patent/JP2015519313A/ja not_active Withdrawn
- 2013-03-13 EP EP13713368.2A patent/EP2841091A1/en not_active Withdrawn
- 2013-03-13 CN CN201380033402.5A patent/CN104411323A/zh not_active Withdrawn
-
2015
- 2015-11-06 US US14/934,196 patent/US20160120954A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015519313A5 (https=) | ||
| AR081042A1 (es) | Peptidos de la superfamilia de glucagon que presentan actividad del receptor acoplado a proteinas g | |
| NO20092774L (no) | HLA-A*1101-begrenset WT1-peptid og farmasoytisk preparat som omfatter dette | |
| JP2010534486A5 (https=) | ||
| JP2012522529A5 (https=) | ||
| EP2573110A3 (en) | Peptide vaccines with Seq Id No: 174, 178, 186 or 194 for cancers expressing tumor-associated antigens | |
| AR108453A1 (es) | Moléculas de unión a antígeno que comprenden un trímero de ligando de la familia del factor de necrosis tumoral (tnf) y un resto de unión a proteína transmembrana monomérica de tipo 1 (pd1) | |
| BR112015032875A2 (pt) | derivados de peptídeos do tipo glp-1, e usos dos mesmos | |
| CY1123997T1 (el) | Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου | |
| WO2013036778A3 (en) | Compstatin analogs with improved pharmacokinetic properties | |
| RU2015146614A (ru) | Конъюгированная вакцина на основе пептида антигена wt1 | |
| UA103882C2 (uk) | Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина | |
| AR064642A1 (es) | Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi | |
| WO2012112690A3 (en) | Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains | |
| JP2013519698A5 (https=) | ||
| RU2016152151A (ru) | Препарат, содержащий фактор viii и пептиды фактора фон виллебранда | |
| JP2015532307A5 (https=) | ||
| NZ701205A (en) | Optimised subcutaneous therapeutic agents | |
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| JP2012102105A5 (https=) | ||
| RU2017126566A (ru) | ВСТРЕЧАЮЩИЕСЯ В ПРИРОДЕ миРНК ДЛЯ КОНТРОЛИРОВАНИЯ ЭКСПРЕССИИ ГЕНОВ И ИХ ПРИМЕНЕНИЕ | |
| MX2025012580A (es) | Un factor de von willebrand recombinante (vwf) y el uso en hemorragia gastrointestinal | |
| WO2015054439A3 (en) | Hybrid factor viii polypeptides for use to treat hemophilia a | |
| JP2017523783A5 (https=) | ||
| EP3208334A3 (en) | Cdc45l peptides and vaccines including the same |